Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, ...

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration by finding that drug manufacturers must obtain pre-approval from HRSA before implementing ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.